Vaxcyte, Inc.PCVXNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +17.64% | +21.49% | +16.01% | +10.11% | +10.78% |
| Weighted Average Shares Diluted Growth | +17.64% | +21.49% | +16.01% | +10.11% | +10.78% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | -100.00% | -100.00% | -97.76% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +149.40% | +61.53% | +58.36% | -10.90% | -13.25% |
| Book Value per Share Growth | +126.54% | +32.76% | +33.29% | -23.12% | -26.67% |
| Debt Growth | +143.33% | +218.05% | +235.58% | +202.02% | +221.81% |
| R&D Expense Growth | +28.29% | +56.61% | +47.66% | +79.53% | +81.16% |
| SG&A Expenses Growth | +62.93% | +64.24% | +49.20% | +41.15% | +12.85% |